Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis.

Abstract

INTRODUCTION:

Preclinical data have revealed that beta-adrenergic stimulation can affect the growth and progression of different types of malignancies. Beta-adrenergic receptor blockers have been associated with improved survival in patients with many types of cancer. We performed a meta-analysis to investigate the association between beta-blocker use and hepatocellular carcinoma (HCC) prognosis.

METHODS:

In this meta-analysis, a full search was conducted using PubMed, the Cochrane library and Embase to identify all relevant studies published up to May 2021. Available hazard ratios (HRs) were extracted for overall survival (OS), cancer-specific survival (CSS) and pooled using a random-effects meta-analysis.

RESULTS:

Four studies involving 7252 patients with HCC met the inclusion criteria and were included in the systemic review. Three studies that reported OS data of 5148 patients were included in the meta-analysis. The random-effects model showed that beta-blocker use was associated with significantly improved OS in HCC (HR = 0.69, 95% CI = 0.54-0.88, P = 0.0031), without significant heterogeneity (I2 = 41%; Q = 6.42, P = 0.18).

CONCLUSION:

This meta-analysis suggested that beta-blocker use can be associated with prolonged OS of patients with HCC.

• Authors: Hyun Chang, Sung Hyun Lee
• Journal: Clinical and experimental medicine (Clin Exp Med) Vol. 23 Issue 3 Pg. 853-858 (Jul 2023) ISSN: 1591-9528 [Electronic] Italy
• PMID: 35737170 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Receptors, Adrenergic, beta

Topics

• Humans
• Carcinoma, Hepatocellular (pathology)
• Liver Neoplasms (pathology)
• Prognosis
• Proportional Hazards Models
• Receptors, Adrenergic, beta